Nathalie, founder, CEO and CSO of HCS Pharma will be present in BIO international convention that takes place in Boston, USA from the 5th to the 8th of June. Is it the place to be for a start-up like HCS Pharma, proposing a breakthrough technology that will revolutionnize the biotechnology Read more…
The Building Biology in 3D symposium of the Society for Laboratory Automation and Screening (SLAS) took place in Cambridge, United Kingdom, on March 20th and 21th 2023. This congress was the opportunity to discover the dynamic scientific environment of Cambridge. Because this event was focusing on 3D cell culture, most Read more…
A driver oncogene is a gene that, when activated by mutation or altered in expression, contributes importantly to the development and progression of cancer. In other words, alteration of this kind of genes lead to the transformation of a normal cell into a cancerous cell by activating signaling pathways involved Read more…
… And it is right ! “Biomimesys technology can bring several advantages in immuno-oncology by providing a more physiologically relevant 3D cell culture model for research. This technology uses a bioinspired extracellular matrix to create a three-dimensional environment that more closely resembles the natural cellular environment. In immuno-oncology, 2D cell Read more…
The event “Research and Innovation 2023 – Accelerating future DD” of The European Laboratory Research and Innovation Group (ELRIG) took place in Cambridge on March 29th and 30th 2023. Our project leader Dr. Veronique De Conto attended this event with our academic partner Dr.Marie Fernandes (CNRS, Oncolille, Canther Lab), who Read more…
HCS Pharma is very pleased to participate to “Building Biology in 3D” symposium of the Society for Laboratory Automation and Screening (SLAS), in Cambridge, United Kingdom 20-21 April 2023. Veronique De Conto, our project leader in in vitro pharmacology will present two digital posters about the use of BIOMIMESYS® hydroscaffold, Read more…
Follow the webinar « From 2D to 3D » with miss Oceane Guyot, R&D dermarto cosmetology Project leader on ; – Tuesday, April 25, 2023 – 9AM (CEST) / 3PM (CST) / 4PM (JST) / 3AM (EST) – Thursday, April 27, 2023 – 5PM (CEST) / 11PM (CST) / 12PM (JST) / 11AM Read more…
It is with great pleasure that we announce the reinforcement of our collaboration about lung cancer between HCS Pharma and TARGET team of the OncoLille Institute (Team “Efficacy and resistance to anti-tumor targeted therapies”, CANTHER UMR9020, Lille, France). Initially supported by Région Hauts-de-France, this project has been initiated in spring Read more…
Zebrafish is a popular model organism for biomedical research worldwide beacause is an ideal model for studying embryonic development and genetic disorders. They have an impressive ability to regenerate damaged tissues, including fins, heart, and spinal cord. And that is why, we are very pleased to inform you that our Read more…
We will be pleased to meet you in Paris from the 28th to 30th of March. Join Thierry DE CATHEU Business Director, Mathieu LAOUENAN Chief Commercial Officer, Paul COUVREUR and Rita HIEN Junior Business Developpers. Meryl Roudaut, our Project leader in metabolic tissues, and our Project director Elodie VANDENHAUTE will Read more…
Organoids are three-dimensional structures made of cells, which can be derived from stem cells to mimic the structure and function of real organs. They are useful tools for studying human development, disease modeling, drug screening, and personalized medicine. Recent advancements in organoid research have focused on improving their complexity and Read more…
Welcome to HCS Pharma series of webinars and please register for free to the ones you want to attend. You will receive the specific Zoom link within a week prior the event.You will learn more about BIOMIMESYS®, an amazing and disruptive technology that reproduces all aspects of the microenvironment (matrix Read more…
We are pleased to participate in ELRIG event about Research an Innovation 2023 – Accelerating future drug discovery” in Cambridge on March 29 and 30th 2023. Veronique De Conto, our project leader in in vitro Pharmacology, is very happy to meet with you and to present you our disruptive technology Read more…
The beginning of 2023 is tremendous for HCS Pharma in terms of new oncology-related collaborative R&D projects, with three of them accepted and granted by ANR (Agence Nationale pour la Recherche) through the Plan France Relance, and by the Région Hauts-de-France through STIMuLE plan. It has been announced in a Read more…
The Brain Week is an international event organized simultaneously in about 100 countries and more than 120 cities in France. Its aim is to raise public awareness of the importance of brain research. It is an opportunity for many researchers to meet the public and share with them the advances Read more…
I will be pleased to be in BIO-Europe Spring in Basel, Switzerland to present BIOMIMESYS, our breakthrough technology and our new results that we have with it. In HCS Pharma, we are reinventing biology with our academic partners by analyzing the impact of changes in the microenvironment on cells and Read more…
After obtaining a Master’s degree in Life Sciences from the “École Pratique des Hautes Études” (Paris Sciences and Letters University) in 2022, Marina Villaverde has just started a PhD thesis. Through the collaboration between the Institute for Regenerative Medicine and Biotherapies and HCS Pharma, this PhD work will focus on Read more…
After a first publication “Development of Liver-on-Chip Integrating a Hydroscaffold Mimicking the Liver’s Extracellular Matrix” in collaboration with the University of Technology of Compiègne (UTC) using the BIOMIMESYS® Liver hydroscaffold™ and HepG2/C3A (hepatocellular carcinoma cell line) in Biochip, the project continue with Rania Chibani, who has joined us for a Read more…
After obtaining this Master’s degree in Biology and Health Science at Lille University in 2022, Nathan Laneret has just begun a PhD thesis under the supervision of Pr. RA Toillon and Dr. Nathalie Maubon thanks to ANRT fundings (CIFRE). Through this collaboration between the Cellular Plasticity and Cancer team from Canther Lab Read more…
It is a pleasure to announce that HCS Pharma has a new collaborative project dealing with Mucins, cancer and drug resistance Team of OncoLille (CANTHER-MUCINE) in the frame of pancreatic cancer, thanks to France Relance plan and Region Hauts-de-France. This project has started in October 2022 for 2 years, and Read more…
Because BIOMIMESYS® is made with the heart, he can also love ! BIOMIMESYS® matrix produced by HCS Pharma is a unique groundbreaking 3D cell culture technology which associates both the properties of a solid scaffold (porosity and structure maintenance) and the properties of a hydrogel (cell-matrix interaction). BIOMIMESYS® matrix are Read more…
It is a pleasure to announce that HCS Pharma has a new collaborative project dealing with Inflammasome et ion channels Team of OncoLille (PHYCELL Lab, INSERM U1003) in the frame of colon cancer, thanks to France Relance plan and Region Hauts-de-France. This project has started in October 2022 for 2 Read more…
We are glad starting a new Year! But nothing better than assessing what happened along the last one to glance back at the road traveled so far… and looking forward to what’s next!